Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Yet another combination to consider after CDK4/6i + ET in HR+ MBC!
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Author(s): Li Chen, MD1,2; Hui Li, MD3; Hao Zhang, MD4; Huawei Yang, MD5; Jun Qian, MD6; Zhihua Li, MD7; Yu Ren, MD8; Shu Wang, MD9; Peifen Fu, MD10; Hongjian Yang, MD11; Yunjiang Liu, MD12; Jing Sun, MD13; Jianyun Nie, MD14; Ruiwen Lei, MD15; Yongzhong Yao, MD16; Anqin Zhang, MD17; Shouman Wang, MD18; Xiaopeng Ma, MD19; Zhong Ouyang, MD20; Hongwei Yang, MD21; Song-Yang Wu, MD1,2; Shuo-Wen Cao, MD1,2; Kun Wang, MD22; Aimei Jiang, MD23; Quchang Ouyang, MD24; Da Pang, MD25; Limin Wei, MD26; Xiaoming Zha, MD27; Yu Shen, PhD28; Xiangwen Qu, MD28; Fei Wu, MD28; Xiaoyu Zhu, PhD28; Zhonghua Wang, MD1,2; Lei Fan, MD1,2; Zhi-Ming Shao, MD1,2;
Source: JAMA. 2025;333(8):673-681. doi:10.1001/jama.2024.23560
Dr. Maen Hussein's Thoughts
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
The CamRelief Randomized Clinical Trial
IMPORTANCE
Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy. Camrelizumab, an anti–PD-1 antibody, has showed antitumor activity in advanced triple-negative breast cancer.
OBJECTIVE
To evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for patients with early or locally advanced triple-negative breast cancer.
DESIGN, SETTING, AND PARTICIPANTS
This randomized, double-blind, phase 3 trial enrolled patients from 40 hospitals in China between November 25, 2020, and May 12, 2023 (data cutoff: September 30, 2023). A total of 441 eligible patients were enrolled.
INTERVENTIONS
Patients were randomized in a 1:1 ratio to receive either camrelizumab 200 mg (n = 222) or placebo (n = 219) combined with chemotherapy every 2 weeks. The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by epirubicin (90 mg/m2) and cyclophosphamide (500 mg/m2) every 2 weeks for 8 weeks.
MAIN OUTCOMES AND MEASURES
The primary end point was pathological complete response (defined as no invasive tumor in breast and lymph nodes [ypT0/Tis ypN0]).
RESULTS
Among 441 females randomized (median age, 48 years), the median (range) follow-up duration from randomization was 14.4 (0.0-31.8) months. Pathological complete response was achieved in 126 patients (56.8% [95% CI, 50.0%-63.4%]) in the camrelizumab-chemotherapy group and 98 patients (44.7% [95% CI, 38.0%-51.6%]) in the placebo-chemotherapy group (rate difference, 12.2% [95% CI, 3.3%-21.2%]; 1-sided P = .004). In the neoadjuvant phase, adverse events of grade 3 or higher occurred in 198 patients (89.2%) in the camrelizumab-chemotherapy group and 182 (83.1%) in the placebo-chemotherapy group; serious adverse events occurred in 77 patients (34.7%) in the camrelizumab-chemotherapy group and 50 (22.8%) in the placebo-chemotherapy group, with fatal adverse events occurring in 2 patients (0.9%) in the camrelizumab-chemotherapy group.
CONCLUSIONS AND RELEVANCE
Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response.
TRIAL REGISTRATION
ClinicalTrials.gov Identifier: NCT04613674
Author Affiliations
1Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; 3Department of Breast Surgery, Sichuan Provincial Cancer Hospital, Chengdu, China; 4Department of Breast Surgery, Nanyang City Center Hospital, Nanyang, China; 5Department of Breast Surgery, Guangxi Medical University Affiliated Cancer Hospital, Nanning, China; 6Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China; 7Breast Center Second Section, The Third Hospital of Nanchang, Nanchang, China; 8Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China; 9Department of Breast Surgery, Peking University People’s Hospital, Beijing, China; 10Department of Breast Surgery, The First Affiliated Hospital of Zhejiang University, Hangzhou, China; 11Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, China; 12Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China; 13The Fifth Ward of Medical Oncology, Anyang Tumour Hospital, Anyang, China; 14Department of Breast Surgery, Yunnan Cancer Hospital, Kunming, China; 15Department of Breast Surgery, Yuebei People’s Hospital, Shaoguan, China; 16Department of Breast Surgery, Nanjing Drum Tower Hospital, Nanjing, China; 17Department of Breast Surgery, Guangdong Women’s and Children’s Hospital, Guangzhou, China; 18Department of Medical Oncology, Xiangya Hospital of Central South University, Changsha; 19Department of Breast Surgery, Anhui Provincial Hospital, Hefei, China; 20Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China; 21Breast and Thyroid Surgery, Suining Central Hospital, Suining, China; 22Breast Center Second Section, Guangdong General Hospital, Guangzhou, China; 23Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China; 24Department of Breast Medicine, Hunan Cancer Hospital, Changsha, China; 25Department of Breast Surgery, Affiliated Cancer Hospital of Harbin Medical University, Harbin, China; 26Department of Breast Surgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China; 27Department of Breast Surgery, Jiangsu Provincial Hospital, Nanjing, China; 28Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China;Related Articles
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
TD beat chemotherapy after failure of hormonal therapy in HER-2 low and ultra low. Wait for the indication.
